DJS Law Group says ARS Pharmaceuticals investors may have securities claim
A DJS Law Group press release says a securities class action against ARS Pharmaceuticals centers on alleged statements about CVS Caremark formulary and coverage timing for neffy.
DJS Law Group says investors in ARS Pharmaceuticals may have claims tied to alleged disclosures about neffy and CVS Caremark timing.
What happened
A DJS Law Group press release dated Aug. 31, 2026, says the firm is reminding investors about a securities class action against ARS Pharmaceuticals, Inc. over alleged violations of federal securities laws.
The release says the case involves ARS, which trades on Nasdaq under the ticker SPRY, and covers shareholders who bought the stock between March 9, 2026, and June 24, 2026. It says the complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5.
Why it matters
The press release says the lawsuit centers on alleged false and misleading statements to the market about the timing of CVS Caremark formulary and coverage approval decisions for neffy. According to the release, the complaint alleges ARS knew the timeline had issues and that the delay would affect commercialization plans.
The release says shareholders may contact the firm about possible lead plaintiff appointments, and that lead plaintiff status is not required to participate in any recovery.
Context and background
ARS Pharmaceuticals is identified in the release as the company behind neffy. The press release does not provide additional details about the underlying business timeline beyond the alleged CVS Caremark-related delay described in the complaint.
DJS Law Group says it focuses on securities class actions, corporate governance litigation, and domestic and international M&A appraisals.
What the firm said
The release includes contact information for David J. Schwartz of DJS Law Group in Eastchester, New York, for investors seeking information about the case.
No response from ARS Pharmaceuticals was included in the press release provided for this report.
What happens next
According to the release, investors who purchased SPRY shares during the class period may contact the firm about their rights and about the lead plaintiff process. The press release does not say when the court will next act in the case.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
Comments ()